FHN vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
FHN presents a stark contrast between attractive valuation and deteriorating fundamental health, highlighted by a weak Piotroski F-Score of 2/9. While the current price of $24.21 is a discount to both the Graham Number ($28.16) and the growth-based Intrinsic Value ($58.7), the low health score and bearish insider activity suggest significant underlying risks. These concerns are partially offset by strong earnings growth (29.3% YoY) and a consistent track record of beating analyst estimates. Consequently, the stock is a high-risk value play where growth metrics clash with poor deterministic health indicators.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
FHN vs JPM: Head-to-Head Comparison
This page compares First Horizon Corporation (FHN) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.